CSIMarket
 


Travere Therapeutics Inc   (TVTX)
Other Ticker:  
 

Travere Therapeutics Inc 's Working Capital Ratio

TVTX's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




TVTX Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 15.79 % 56.25 % 73.62 % 86.53 % 82.72 %
Y / Y Current Assets Change -7.64 % 6.73 % 11.69 % 17.11 % 14.54 %
Working Capital Ratio MRQ 4.08 4.71 5.28 4.7 5.12
Overall Ranking # # # # #
Seq. Current Liabilities Change 5.25 % 4.2 % -3.72 % 9.65 % 42.03 %
Seq. Current Assets Change -8.85 % -7.02 % 8.28 % 0.65 % 5.33 %



Working Capital Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Working Capital Ratio fell to 4.08 above Travere Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry Travere Therapeutics Inc booked the highest Working Capital Ratio than Travere Therapeutics Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is TVTX most successful ?
Working Capital Ratio TVTX on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Working Capital Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Travere Therapeutics Inc 's Current Liabilities $ 131 Millions Visit TVTX's Balance sheet
Travere Therapeutics Inc 's Current Assets $ 535 Millions Visit TVTX's Balance sheet
Source of TVTX's Sales Visit TVTX's Sales by Geography


Cumulative Travere Therapeutics Inc 's Working Capital Ratio

TVTX's Working Capital Ratio for the trailling 12 Months

TVTX Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 15.79 % 56.25 % 73.62 % 86.53 % 82.72 %
Y / Y Current Assets TTM Growth -7.64 % 6.73 % 11.69 % 17.11 % 14.54 %
Working Capital Ratio TTM 4.68 4.95 5.37 5.9 6.68
Total Ranking TTM # 50 # 440 # 1081 # 849 # 0
Seq. Current Liabilities TTM Growth 5.25 % 4.2 % -3.72 % 9.65 % 42.03 %
Seq. Current Assets TTM Growth -8.85 % -7.02 % 8.28 % 0.65 % 5.33 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to rise in Current Liabilities in the III. Quarter to $131.03 millions, average cumulative Working Capital Ratio decreased to 4.68 below the Travere Therapeutics Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 4 other companies have achieved higher Working Capital Ratio than Travere Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. 50.

Explain Working Capital Ratio
Where is TVTX most successful ?
Working Capital Ratio TVTX on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 5
Healthcare Sector # 10
Within the Market # 50


TTM Working Capital Ratio Statistics
High Average Low
6.62 4.69 2.34
(Mar 31 2021)   (Dec. 30, 2015)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Oragenics Inc   11.20 $ 14.513  Millions$ 1.296  Millions
Prometheus Biosciences Inc   11.19 $ 266.056  Millions$ 23.779  Millions
Sio Gene Therapies Inc   11.13 $ 53.739  Millions$ 4.830  Millions
Inozyme Pharma Inc   11.11 $ 145.926  Millions$ 13.133  Millions
Dyne Therapeutics Inc   11.07 $ 258.234  Millions$ 23.321  Millions
Biomea Fusion Inc   11.03 $ 138.861  Millions$ 12.589  Millions
Hillstream Biopharma Inc   10.93 $ 7.833  Millions$ 0.717  Millions
Entrada Therapeutics Inc   10.89 $ 234.733  Millions$ 21.551  Millions
Rhythm Pharmaceuticals inc   10.85 $ 361.874  Millions$ 33.354  Millions
Igm Biosciences Inc   10.79 $ 479.966  Millions$ 44.484  Millions
Eledon Pharmaceuticals Inc   10.76 $ 67.565  Millions$ 6.280  Millions
Genprex Inc   10.71 $ 26.308  Millions$ 2.457  Millions
Context Therapeutics Inc   10.66 $ 41.939  Millions$ 3.933  Millions
Indaptus Therapeutics Inc   10.64 $ 29.594  Millions$ 2.782  Millions
Pyxis Oncology Inc   10.62 $ 202.808  Millions$ 19.095  Millions
Aadi Bioscience Inc   10.61 $ 189.863  Millions$ 17.891  Millions
Shattuck Labs Inc   10.53 $ 201.516  Millions$ 19.139  Millions
Salarius Pharmaceuticals inc   10.47 $ 17.966  Millions$ 1.717  Millions
Satsuma Pharmaceuticals Inc   10.42 $ 67.563  Millions$ 6.486  Millions
Prothena Corporation Public Limited Company  10.37 $ 524.562  Millions$ 50.598  Millions
Bioxcel Therapeutics Inc   10.34 $ 241.661  Millions$ 23.378  Millions
Guardion Health Sciences Inc   10.33 $ 17.811  Millions$ 1.724  Millions
Rocket Pharmaceuticals Inc   10.31 $ 311.131  Millions$ 30.181  Millions
Reviva Pharmaceuticals Holdings Inc   10.24 $ 24.041  Millions$ 2.348  Millions
Magenta Therapeutics Inc   10.22 $ 132.097  Millions$ 12.921  Millions
Chinook Therapeutics Inc   10.20 $ 381.670  Millions$ 37.426  Millions
Vanda Pharmaceuticals Inc   10.12 $ 507.106  Millions$ 50.125  Millions
Kempharm Inc  10.10 $ 85.133  Millions$ 8.431  Millions
Acasti Pharma Inc   10.04 $ 37.505  Millions$ 3.735  Millions
Oncternal Therapeutics Inc   9.97 $ 74.790  Millions$ 7.504  Millions

Date modified: 2022-10-28T16:01:35+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

FRTX's Profile

Stock Price

FRTX's Financials

Business Description

Fundamentals

Charts & Quotes

FRTX's News

Suppliers

FRTX's Competitors

Customers & Markets

Economic Indicators

FRTX's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071